FDA NDA Acceptance and Strong RINGSIDE Data Support Immunome Buy Rating and Unchanged $40 Price Target
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Charles Zhu maintained a Buy rating on Immunome (IMNM) with an unchanged $40 price target. The bullish stance is driven by the FDA's acceptance of the NDA for varegacestat, strong Phase 3 RINGSIDE data showing superior efficacy, and solid pipeline execution. Additionally, J.P. Morgan also issued a Buy rating on June 29.
LifeSci Capital analyst Charles Zhu has maintained their bullish stance on IMNM stock, giving a Buy rating on June 29.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Charles Zhu has given his Buy rating due to a combination of factors tied to Immunome’s lead asset and overall execution. He highlights that the FDA’s acceptance of the NDA for varegacestat, with a standard review and an April 28, 2027 PDUFA date, locks in a clear path to potential commercialization in desmoid tumors and confirms the program is progressing as planned.
Zhu also points to the strong Phase 3 RINGSIDE data for varegacestat, including robust response and progression-free survival metrics that he views as superior to the only approved oral GSI competitor, particularly given Immunome’s once-daily dosing profile. In addition, he underscores continued pipeline advancement across ADC programs and solid operational execution, supporting his unchanged $40 price target and reinforcing his conviction that Immunome offers attractive upside from current levels.
Charles Zhu has given his Buy rating due to a combination of factors tied to Immunome’s lead asset and overall execution. He highlights that the FDA’s acceptance of the NDA for varegacestat, with a standard review and an April 28, 2027 PDUFA date, locks in a clear path to potential commercialization in desmoid tumors and confirms the program is progressing as planned.
Zhu also points to the strong Phase 3 RINGSIDE data for varegacestat, including robust response and progression-free survival metrics that he views as superior to the only approved oral GSI competitor, particularly given Immunome’s once-daily dosing profile. In addition, he underscores continued pipeline advancement across ADC programs and solid operational execution, supporting his unchanged $40 price target and reinforcing his conviction that Immunome offers attractive upside from current levels.
In another report released on June 29, J.P. Morgan also maintained a Buy rating on the stock with a $0.00 price target.